Company

Micro-X Limited

ASX:MX1

Micro-X designs and manufactures X-ray and CT imaging hardware built on carbon-nanotube ("cold cathode") emitters, which let the tube be far smaller and lighter than conventional thermionic X-ray tubes. Its commercial product is the Rover / Rover Plus mobile digital radiography unit, a portable X-ray system used where patients cannot easily be moved to a fixed radiology suite: emergency departments, intensive care, operating theatres, remote and field settings. In development is an ultra-lightweight head CT scanner intended to be carried in an ambulance so that stroke can be imaged and triaged before the patient reaches hospital, plus earlier-stage portable full-body CT and lung CT work. The longevity relevance is infrastructural rather than therapeutic: it addresses point-of-care imaging for immobile and frail patients and time-to-diagnosis in stroke, a condition whose incidence rises sharply with age. It is not a geroscience or ageing-biology company, and the Micro-X site does not itself market Rover as an aged-care product, so the aged-care framing should be treated as an inference about the use case rather than a company claim. Micro-X also sells non-medical security screening products (baggage and checkpoint scanners), so medical imaging is only part of the revenue base.

At a glance

Listing
ASX:MX1
Category
Diagnostics
Headquarters
Adelaide, South Australia, Australia
Market cap
Not disclosed

Thesis

Why it is in this universe

Category
Diagnostics
Market
Australia
Recent inflection
On 24 September 2025 Micro-X announced it had been awarded a $4.4 million grant to fund a world-first trial of a stroke-capable ambulance integrating its ultra-lightweight head CT scanner into frontline emergency services. As of the company's 9 July 2026 investor newsletter, the head CT programme had progressed to human imaging trials, alongside portable full-body CT development under the ARPA-H PARADIGM contract (announced 13 February 2025, up to US$16.4m / A$25m). Source: Micro-X news page, micro-x.com/news/.
Services
None recorded
People tracked
None on file

Market data

Listing and scale

MetricDetail
ExchangeASX
TickerASX:MX1
Secondary listingNone
Market capNot disclosed
StatusListed and trading
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.

Get in touch

Contact

Address
Adelaide, South Australia, Australia
Phone
No public number published
Email
No public address published

Offering

What it sells today

No commercial services are recorded for this company yet.

Recent inflection

What moved lately

On 24 September 2025 Micro-X announced it had been awarded a $4.4 million grant to fund a world-first trial of a stroke-capable ambulance integrating its ultra-lightweight head CT scanner into frontline emergency services. As of the company's 9 July 2026 investor newsletter, the head CT programme had progressed to human imaging trials, alongside portable full-body CT development under the ARPA-H PARADIGM contract (announced 13 February 2025, up to US$16.4m / A$25m). Source: Micro-X news page, micro-x.com/news/.

Keep reading

Related coverage from the newsroom.

Suggest an updateJoin the community

Sources

What this profile is built on

Every entity profile on variis is sourced. Not investment advice.